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Aortic Stiffness Is Increased in Hypertrophic
Cardiomyopathy With Myocardial Fibrosis
Novel Insights in Vascular Function From Magnetic Resonance Imaging
Thananya Boonyasirinant, MD,*§ Prabhakar Rajiah, MD,* Randolph M. Setser, DSC,*
Michael L. Lieber, MS,† Harry M. Lever, MD,‡ Milind Y. Desai, MD,*‡ Scott D. Flamm, MD*‡
Cleveland, Ohio; and Bangkok, Thailand
Objectives The aim of the study was to determine if patients with hypertrophic cardiomyopathy (HCM), both with and with-
out myocardial fibrosis, have altered aortic stiffness as assessed by magnetic resonance imaging (MRI) pulse
wave velocity (PWV) measurements.
Background Abnormal aortic stiffness implies an unfavorable prognosis and has been established in a variety of aortic dis-
eases and ischemic cardiomyopathy. However, the relationship between aortic stiffness and HCM has not been
studied previously.
Methods The study was institutional review board approved and Health Insurance Portability and Accountability Act of
1996 compliant. Velocity-encoded MRI was performed in 100 HCM and 35 normal control subjects. PWV was
determined between the mid-ascending and -descending thoracic aorta. Delayed-enhancement MRI was ac-
quired for identification of myocardial fibrosis.
Results Mean age was 52.4 years in HCM and 45.3 years in control subjects. The prevalence of myocardial fibrosis in
HCM was 70%. PWV was significantly higher in HCM patients compared with control subjects (8.72  5.83 m/s
vs. 3.74  0.86 m/s, p  0.0001). PWV was higher (i.e., increased aortic stiffness) in HCM patients with myo-
cardial fibrosis than in those without (9.66  6.43 m/s vs. 6.51  3.25 m/s, p  0.005).
Conclusions Increased aortic stiffness, as indicated by increased PWV, is evident in HCM patients, and is more pronounced in
those with myocardial fibrosis. Further, aortic stiffening may adversely affect left ventricular performance. In ad-
dition, increased aortic stiffness correlates with myocardial fibrosis, and may represent another potentially im-
portant parameter for risk stratification in HCM, warranting further study. (J Am Coll Cardiol 2009;54:255–62)
© 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.060l
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typertrophic cardiomyopathy (HCM) is a complex genetic
ardiac disorder that has been a subject of intense scrutiny
nd investigation for 5 decades. It is the most common
ause of sudden cardiac death in young people, particularly
n athletes (1,2). As a result of the clinical and phenotypic
eterogeneity of HCM, it is challenging to determine a
ubset of patients who will have a higher risk of sudden
ardiac death and adverse prognosis. Myocardial fibrosis
etected by delayed-enhancement magnetic resonance im-
ging (DE-MRI) is an adverse risk factor, as it represents a
ubstrate for ventricular arrhythmias. There is an increased
rom the *Cardiovascular Imaging Laboratory, Imaging Institute, †Quantitative
ealth Sciences, Lerner Research Institute, and ‡Cardiovascular Medicine, Heart
nd Vascular Institute, Cleveland Clinic, Cleveland, Ohio; and the §Division of
ardiology, Department of Internal Medicine, Siriraj Hospital, Mahidol University,
angkok, Thailand.d
Manuscript received January 14, 2009; revised manuscript received March 10,
009, accepted March 23, 2009.ikelihood and frequency of ventricular arrhythmias and
udden cardiac death in those with myocardial fibrosis (3,4).
In recent years, increased emphasis has been placed on
he association of aortic stiffness with aging, as well as a
See page 263
ariety of cardiovascular diseases, including atherosclerosis,
eart failure, hypertension, diabetes, and aortopathies (5,6).
ortic stiffness potentially may be compromised in HCM,
s a result of neurohormonal disturbances, endothelial
ysfunction, abnormal baroreceptor reflex in the left ventri-
le, and intrinsic aortic wall fibrosis. However, aortic stiff-
ess has not been studied in patients with HCM.
Assessment of aortic stiffness with velocity-encoded
agnetic resonance imaging (VENC-MRI) is an attrac-
ive and promising strategy as this measurement does not
epend on the knowledge of central arterial pressure or
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Abnormal Aortic Stiffness in HCM July 14, 2009:255–62geometrical assumptions that
may limit other measurement
tools (7–10). The role of car-
diac magnetic resonance imag-
ing (MRI) in the evaluation of
HCM has been well established
in the precise assessment of left
ventricular mass, function, and
the evaluation of myocardial fi-
brosis (11,12). The addition of
aortic stiffness measurements using
pulse wave velocity (PWV) mea-
surements may enhance the value
of MRI in further characterization
of HCM, and provide an impor-
tant tool in risk stratification.
Therefore, the objective of the
present study was to determine if
patients with HCM, both with
and without myocardial fibrosis,
y DE-MRI have altered aortic stiffness as assessed by MRI
WV measurements.
ethods
his was a retrospective, single-institution study with approval
rom the local institutional review board for waiver of individ-
al informed consent.
atient population. One hundred consecutive patients
ith HCM and 35 normal control subjects were included
n this study. Diagnosis of HCM was established based
n standard clinical criteria using history, physical exam-
nation, electrocardiogram, and echocardiogram. Exclu-
ion criteria were concomitant aortic diseases such as
ortic coarctation, Marfan syndrome, and prior history of
eptal alcohol ablation or myectomy. The presence of left
entricular outflow tract (LVOT) obstruction was as-
essed by resting LVOT gradient using transthoracic
chocardiography. Normal control subjects had no iden-
ified cardiac or aortic abnormalities.
RI. Cardiac MRI was performed with a 1.5-T MRI
canner (Avanto, Siemens Medical Solutions, Erlangen,
ermany). After scout imaging to locate the cardiac axes,
lectrocardiogram-triggered nonbreath-hold black blood
repared half Fourier acquisition in steady state images were
cquired in the axial orientation for a total of 40 slices. The
maging parameters were: echo time (TE)  20 ms;
epetition time (TR)  800 ms; refocusing flip angle 
60°; slice thickness  6 mm; field of view in x axis (FOVx)
240 to 360 mm; field of view in y axis (FOVy)  300 to
80 mm; typical matrix size  124  192; and typical
cquired spatial resolution  2.4  1.8 mm.
Velocity-encoded imaging was acquired using a breath-
old, retrospectively electrocardiogram-gated gradient echo
ulse sequence at the level of the pulmonary trunk to
Abbreviations
and Acronyms
DE-MRI  delayed-
enhancement magnetic
resonance imaging
FOV  field of view
HCM  hypertrophic
cardiomyopathy
LVOT  left ventricular
outflow tract
MRI  magnetic resonance
imaging/image
PWV  pulse wave velocity
TE  echo time
TR  repetition time
VENC-MRI  velocity-
encoded magnetic
resonance imaging/imageeasure through-plane flow in the mid-ascending and udescending aorta with the following parameters: TE  3.1
s; TR 5.0 ms; flip angle 30°; slice thickness 6 mm;
OVx  240 to 360 mm; FOVy  300 to 380 mm; typical
atrix size  128  256; typical acquired spatial resolution
2.3  1.3 mm; temporal resolution  25 to 35 ms; and
elocity encoding  200 cm/s.
To assess the presence of myocardial fibrosis, delayed-
nhancement images were acquired in contiguous short-
xis, and 2-, 3-, and 4-chamber long-axis orientations, with
breath-hold inversion recovery spoiled gradient echo
equence: TE  4 ms; TR  8 ms; flip angle  30°;
andwidth  140 Hz/pixel; 23 k-space lines acquired every
ther R-R interval; FOVx  260 to 360 mm; FOVy  300
o 360 mm; typical matrix size  152  256; and typical
cquired spatial resolution  2.0  1.3 mm. Images were
cquired 15 to 20 min after intravenous injection of 0.2
mol/kg gadolinium dimeglumine (Magnevist, Berlex Imag-
ng, Wayne, New Jersey) during successive 8 to 10 s breath-
olds. For each individual patient, the inversion time (range
25 to 275 ms) was optimized to null viable myocardium.
mage analysis. Using dedicated cardiovascular image
nalysis software (Argus, Siemens Medical Solutions), the
ontours of the mid-ascending and -descending aorta were
rawn. The flow (in m/s) at these 2 levels was obtained from
he velocity data of each voxel in all phases of the cardiac
ycle. From the corresponding flow-time curves, the arrival
f the foot of the pulse wave was measured as the point of
nterception of the linear extrapolation of the steep early
ystolic slope and the baseline. Multiplanar reconstructions
f the axial half Fourier acquisition in steady state images
ere performed to measure the aortic path length. The
enterline was drawn on a reconstructed sagittal view from
he level of the mid-ascending aorta to the mid-descending
orta, corresponding to the same level where the VENC-
RI was acquired (Fig. 1). The PWV, assessed between
he mid-ascending and -descending aorta, was calculated
ccording to the following formula:
PWV
 x
 t
(m⁄s)
here  x was the aortic path length between the midas-
ending and mid-descending aorta, and  t was the time
elay between the arrival of the foot of the pulse wave at
hese levels (7,13).
The presence or absence of myocardial fibrosis was
etermined from DE-MRI slices obtained in the short-axis,
nd 2-, 3-, and 4-chamber views, without knowledge of the
esults of PWV measurements.
To determine intraobserver and interobserver reproduc-
bility, the data of randomly selected patients (40 HCM and
0 control subjects) were reanalyzed by the same observer
T.B.) 4 weeks after the initial analysis, and by a second
ndependent observer (P.R.), blinded to the initial results.
tatistical analysis. All statistical analyses were performed
sing the statistical software program (version 9.1, SAS
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July 14, 2009:255–62 Abnormal Aortic Stiffness in HCMnstitute, Cary, North Carolina). Continuous data were
xpressed as mean values and corresponding SDs, whereas
ichotomous data were presented as numbers and percent-
ges. Categorical variables were compared among the 3
atient groups using chi-square tests; continuous variables
ere compared using a 1-way analysis of variance. When
he overall test was found to be significant (p  0.05), the
pairwise comparisons were performed using Bonferroni
djustments to control the overall type I error rate. The
nalysis of covariance was used to demonstrate the differ-
nce in PWV among HCM patients and normal control
ubjects, adjusting for age. Further, the differences in PWV
etween HCM patients with and without fibrosis, and
CM patients with and without LVOT obstruction were
Figure 1 Measurement of Time Delay Between Pulse Waves an
(Left) Through-plane velocity-encoded magnetic resonance imaging at midascendin
ing flow measurement at midascending (red line) and mid-descending thoracic aor
structed oblique sagittal view.
Characteristics of HCM Patients and Control SuTable 1 Characteristics of HCM Patients an
HCM
Fibrosis (n  70)
Age (yrs) 51.7 16.7
Men/women 46 (66)/24 (34)
Height (cm) 171.9 11.5
Weight (kg) 86.2 15.6
Body surface area (mm2)* 2.0 0.2
Systolic blood pressure (mm Hg) 120 14
Diastolic blood pressure (mm Hg) 76 14
Pulse pressure (mm Hg) 46 15
Heart rate (beats/min) 65 11†
Medications
Beta-blocker 52 (75.4)*†
Calcium-channel blocker 13 (18.8)
ACEI 5 (7.2)
ARB 2 (2.9)
Data aremean SD or n (%). *According to the formula: [height (cm
correction) indicated by  and †.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin recepnalyzed by analysis of covariance, adjusting for age. Ad-
ustments for the multiple comparisons involving fibrosis
nd LVOT were not made. Intraobserver and interobserver
ean differences of PWV were tested for statistical signif-
cance using the Bland-Altman method (14). Further, the
orrelations between the PWV of the 2 measurements from
he same observer and between the PWV from the 2
bservers were evaluated. A p value of0.05 was considered
tatistically significant.
esults
aseline characteristics. Baseline characteristics and basic
RI parameters are shown in Tables 1 and 2. Mean age was
rtic Path Length
circles) and mid-descending thoracic aorta (blue circles). (Middle) Correspond-
e line). (Right) The measurement of aortic path length from a multiplanar recon-
sntrol Subjects
ents
Control Subjects
(n  35) p Valueo Fibrosis (n  30)
54.0 14.5 45.3 17.8 0.078
17 (57)/13 (43) 19 (54)/16 (46) 0.462
171.5 11.4 170.7 11.6 0.904
90.3 22.2 90.9 16.0 0.390
2.1 0.3 2.1 0.2 0.467
126 14 120 16 0.210
78 9 74 12 0.454
48 9 46 12 0.759
70 12 72 10† 0.006
20 (66.7)* 13 (37)† 0.001
7 (23.3) 4 (11.4) 0.440
3 (10.0) 4 (11.4) 0.760
4 (13.3) 4 (11.4) 0.112
ght (kg)/3,600]; significantly different pairs of groups (after Bonferronid Ao
g (red
ta (blubjectd Co
Pati
N
)weitor blocker; HCM  hypertrophic cardiomyopathy.
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Abnormal Aortic Stiffness in HCM July 14, 2009:255–621.7 16.7 years in HCM patients with fibrosis, 54.0 14.5
ears in HCM patients without fibrosis, and 45.3  17.8
ears in control subjects. The prevalence of myocardial
brosis in HCM patients was 70%. LVOT obstruction
resting gradient 30 mm Hg) was present in 77%. There
as no correlation between LVOT obstruction and myo-
ardial fibrosis or ascending aortic diameters (p  0.96 and
 0.85, respectively).
ortic PWV. The PWV could be determined in all pa-
ients and normal control subjects, with good quality
elocity-encoded images and corresponding flow-time
urves. The PWV, adjusted for age, was significantly greater
n patients with HCM compared with normal control
ubjects (8.72  5.83 m/s vs. 3.74  0.86 m/s, p  0.0001)
Fig. 2, Table 2). In addition, HCM patients with myocar-
ial fibrosis had significantly higher PWV than HCM
MRI Parameters in HCM Patients and Control STable 2 MRI Parameters in HCM Patients a
HCM
Fibrosis (n  70)
LVEDV (ml) 178.0 50.7*
LVESV (ml) 72.8 32.5*
LVEF (%) 60.6 7.5*
LV mass (g) 172.7 67.0*
Ascending aortic diameter (cm) 2.9 0.3
Descending aortic diameter (cm) 2.2 0.4
PWV (m/s) 9.66 6.43*†
Significantly different pairs of groups (after Bonferroni correction) ind
HCM hypertrophic cardiomyopathy; LV left ventricular; LVEDV
LVESV  left ventricular end-systolic volume; MRI  magnetic resona
Figure 2 PWV in Control Subjects, HCM Patients
Without Fibrosis, and HCM Patients With Fibrosis
The pulse wave velocity (PWV) (mean  SD) in normal control subjects, hyper-
trophic cardiomyopathy (HCM) patients without myocardial fibrosis, and HCM
patients with myocardial fibrosis was 3.74  0.86 m/s, 6.51  3.25 m/s,
and 9.66  6.43 m/s, respectively. Circles  mean; whiskers  95% confi-
dence intervals.matients without myocardial fibrosis (9.66  6.43 m/s vs.
.51  3.25 m/s, p  0.005). Short-axis cine steady-state
ree-precession and DE-MRI, flow time curves, and PWV
easurements for these 3 subsets are illustrated in Figures 3 to 5.
owever, there was no significant difference in PWV values
etween HCM patients with and without LVOT obstruc-
ion (p  0.151).
eproducibility of PWV measurements. There was good
ntraobserver and interobserver reproducibility for the PWV
easurements. The mean PWV  SD values were 7.09 
.05 m/s and 7.07  4.07 m/s (r  0.99) for the first
bserver (T.B.) in the initial analysis and 4 weeks later,
espectively, and 7.31  4.27 m/s (r  0.97) for the second
bserver (P.R.) in the initial analysis. Using the Bland-
ltman method, intraobserver mean differences for 2 mea-
urements of PWV were 0.03  0.48 (p  0.64), and
nterobserver mean differences were 0.19  1.10 (p 
.136), respectively (Fig. 6).
iscussion
his study is the first to demonstrate abnormal aortic
tiffness in HCM patients as indicated by altered PWV
easurements. In addition, the abnormality was more
ronounced in the presence of myocardial fibrosis. Increased
ortic stiffness may affect ventriculo-vascular coupling, and,
s a consequence, left ventricular performance. Abnormal
ascular function may be a novel parameter for risk strati-
cation in HCM patients.
ortic stiffness. There is increasing evidence to suggest
hat abnormalities in aortic stiffness correlate with aging and
athologic states such as atherosclerosis, congestive heart
ailure, hypertension, diabetes, and aortic disorders such as
arfan syndrome, and aortic aneurysm (10,15–18). In
ddition, central arterial stiffness has been highlighted as an
ndependent prognosticator of cardiovascular events in some
opulations (6,19–21).
A wide variety of methods have been proposed for the
valuation of aortic stiffness (22,23). Most of these tech-
iques require knowledge of area and pressure, the latter
btained directly only by invasive means. Noninvasive
tsntrol Subjects
nts
Control Subjects
(n  35) p Valueo Fibrosis (n  30)
151.1 42.6* 150.6 42.0 0.010
54.5 21.3* 64.7 21.2 0.014
65.1 5.8*† 59.5 5.5† 0.004
142.4 52.9† 82.0 14.2*† 0.0001
2.9 0.2 2.8 0.4 0.106
2.3 0.3 2.1 0.3 0.120
6.51 3.25* 3.74 0.86† 0.0001
y * and †.
tricular end-diastolic volume; LVEF left ventricular ejection fraction;
ging; PWV  pulse wave velocity.ubjecnd Co
Patie
N
icated bethods rely on brachial pressure measured by a sphygmo-
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July 14, 2009:255–62 Abnormal Aortic Stiffness in HCManometer acting as a surrogate of central aortic pressure.
his technique is a fairly imprecise approximation, as
ressure amplification may be a significant hindrance to
irectly equate peripheral to central pressure (19,24). Fur-
her, this technique assumes lack of hemodynamically sig-
ificant narrowings or obstruction between the central and
eripheral arterial bed. In addition, cardiovascular risk corre-
ates better to central rather than peripheral pressure (19,25).
PWV is a well-accepted index of arterial stiffness with
igh reproducibility, and, moreover, without the central
Figure 3 PWV Measurement in an HCM Patient With Myocardi
(Left) Steady-state free-precession static cine image from end-diastole (top) demo
enhancement in the septum (bottom), consistent with myocardial fibrosis. (Right)
(blue line). The measurements of arrival time at midascending and mid-descendin
calculated PWV is: [12.80 cm/(24.8  12.1 ms)]  10.08 m/s. Abbreviations as
Figure 4 PWV Measurement in an HCM Patient Without Myoca
(Left) Steady-state free-precession static cine image from end-diastole demonstra
phied region, implying absence of myocardial fibrosis (bottom). (Right) Flow meas
measurements of arrival time at midascending and mid-descending aorta are 21.2
is: [12.84 cm/(46.5  21.2 ms)]  5.08 m/s. Abbreviations as in Figure 2.ressure assumption (20). The principle that a pulse wave
ravels faster in a rigid than a distensible tube enables
stimation of regional mechanical wall properties. The
WV assessed by ultrasound or tonometry has inherent
imitations, such as the estimation of propagation distance
f the traveling pulse from the surface, and the limited
coustic window for the assessment of deep arteries such as
he aorta (26). In contrast, MRI can display the anatomy of
essels in any plane, and velocity-encoded sequences can
oninvasively measure blood flow in any direction or orien-
rosis
es moderate septal hypertrophy, along with patchy, midmyocardial delayed
measurement at midascending (red line) and mid-descending thoracic aorta
are 12.1 and 24.8 ms, respectively. The aortic path length is 12.80 cm. The
ure 2.
Fibrosis
ld septal hypertrophy (top). There is no delayed enhancement in the hypertro-
nt at midascending (red line) and mid-descending thoracic aorta (blue line). The
6.5 ms, respectively. The aortic path length is 12.84 cm. The calculated PWVal Fib
nstrat
Flow
g aorta
in Figrdial
tes mi
ureme
and 4
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Abnormal Aortic Stiffness in HCM July 14, 2009:255–62Figure 5 PWV Measurement in a Normal Control Subject
(Left) Steady-state free-precession static cine image from end-diastole demonstrates normal wall thickness (top), while delayed enhancement imaging demonstrates
absence of myocardial fibrosis (bottom). (Right) Flow measurement at midascending (red line) and mid-descending thoracic aorta (blue line). The measurements of
arrival time at midascending and mid-descending aorta are 20.8 and 62.4 ms, respectively. The aortic path length is 12.89 cm. The calculated pulse wave velocity
(PWV) is: [12.89 cm/(62.4  20.8 ms)]  3.10 m/s.Figure 6 Intraobserver and Interobserver Reproducibility
(Top) The correlation between the pulse wave velocity (PWV) measurements between 2 measurements in the same observer and between 2 independent observers
(n  60 for both). (Bottom) Bland-Altman plots of the PWV measurements between 2 measurements in the same observer and between 2 independent observers
(n  60 for both).
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July 14, 2009:255–62 Abnormal Aortic Stiffness in HCMation. The PWV calculated by VENC-MRI does not
epend on knowledge of central arterial pressure or geomet-
ical assumptions that may limit other established measure-
ent tools (7–10,27).
tiology of abnormal aortic stiffness. In spite of emerging
vidence of abnormal aortic stiffness in a variety of cardio-
ascular diseases, vascular stiffness has not previously been
tudied in the HCM population. In our study, patients with
CM manifested a significantly higher PWV, indicating
ncreased aortic stiffness, and PWV was more pronounced
n the presence of myocardial fibrosis. The precise etiology
or this vascular dysfunction is uncertain, but potential
ontributors include neurohormonal disturbances, endothe-
ial dysfunction, abnormal left ventricular baroreceptor re-
ponse, and intrinsic aortic wall fibrosis specific to HCM.
eurohormonal changes may result from elevated left ventric-
lar pressure. An activated renin-angiotensin-aldosterone sys-
em and norepinephrine contribute to vasoconstriction and
odium retention in the vascular wall (17,28). Further, the
ffect of angiotensin II may result in vascular wall structure
hanges (29). Endothelial dysfunction affects pulsatile
ressure buffering and vasodilation of the arterial system
hrough the elaboration of vasoactive substances, such as
ndothelial-derived relaxing factor (22,29). HCM pa-
ients also may have abnormal left ventricular barorecep-
or stimulation, resulting in inappropriate vasodilation
30). Vasoconstrictor response during exercise has been
hown to be inhibited or reversed in patients with severe
ortic stenosis, potentially from abnormal reflex in left
entricular baroreceptor stimulation (31). Finally, intrin-
ic aortic wall fibrosis in HCM may be an alternative
ontributor to aortic stiffening; this remains an intriguing
onsideration given the known interstitial myocardial
brosis present in a subset of HCM patients, but was not
irectly evaluated in this study. In addition, the associa-
ion of increased aortic stiffness with HCM and myocar-
ial fibrosis may reflect the severity of myocardial in-
olvement and left ventricular performance (32).
ffects of impaired aortic stiffness. Increased aortic stiff-
ess is an important pathophysiologic feature that leads to
ugmented systolic pressure and attenuated diastolic pres-
ure, resulting in elevated pulse pressure (19,33). Higher
ulse pressure may be responsible for arterial medial dam-
ge, pressure overload, and left ventricular hypertrophy
34–36). Increased left ventricular afterload causes stiffening
f the left ventricle and increased wall tension, which
dversely alters ventriculo-vascular coupling and detrimen-
ally impacts on ventricular performance and diastolic relax-
tion (37). As well, lower diastolic pressure induces a
eduction of the coronary perfusion. Stiffening of the aorta
ay contribute to limited exercise capacity via the inability
o generate adequate cardiac output and reduction in skel-
tal muscle perfusion during exercise (17,38). As further
vidence, the relationship between ventriculo-vascular
tiffening index, assessed by MRI, and maximum oxygenonsumption has been demonstrated in patients with
CM (39).
Abnormal vascular function may relate to hypotensive
esponse during exercise, one of the risk factors for sudden
ardiac death. It had been assumed that exercise-induced
ypotension was related to the inability to maintain stroke
olume during tachycardia. However, an invasive hemody-
amic study demonstrated that hypotension was related to a
all in vascular resistance from an abnormal vascular re-
ponse, and occurred despite an appropriate rise in cardiac
ndex (30). Impaired vascular function, as indicated by
bnormal PWV, may reflect this abnormal vascular re-
ponse. This hypothesis, however, requires a further com-
rehensive study.
linical implication. As increased aortic stiffness leads to
etrimental consequences on left ventricular performance
nd cardiovascular outcomes, this parameter may become an
ntegral part of clinical risk stratification. Abnormal aortic
tiffness in the already stiffening hypertrophic ventricle
otentially leads to an even stiffer ventricle and development
f symptoms. In addition to the previously established role
f MRI in patients with HCM, PWV measurement with
ENC-MRI may provide further information on vascular
tiffness. This addition potentially enhances the already
omprehensive role of MRI in the evaluation of HCM,
hich cannot be provided by any other single imaging
odality.
uture direction. This study introduces a vascular element
o this complex cardiomyopathy. The cause of abnormal
ortic stiffness, its relationship with other traditional risk
arkers such as left ventricular thickness and mass, and the
mpact on clinical outcomes warrant further investigation.
onclusions
n addition to well-established myocardial abnormalities,
CM is also associated with abnormal aortic stiffness,
articularly in the presence of myocardial fibrosis. This
ovel parameter may become a complementary component
n risk stratification of HCM patients.
eprint requests and correspondence: Dr. Scott D. Flamm,
ardiovascular Imaging Laboratory, J1-4, Imaging Institute,
leveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195.
-mail: flamms@ccf.org.
EFERENCES
1. Maron BJ. Sudden death in young athletes. N Engl J Med 2003;349:
1064–75.
2. Maron BJ, McKenna WJ, Danielson GK, et al. ACC/ESC clinical
expert consensus document on hypertrophic cardiomyopathy: a report
of the American College of Cardiology Foundation Task Force on
Clinical Expert Consensus Documents and the European Society of
Cardiology Committee for Practice Guidelines (Committee to De-
velop an Expert Consensus on Hypertrophic Cardiomyopathy). J Am
Coll Cardiol 2003;42:1687–713.3. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC,
Pennell DJ. Toward clinical risk assessment in hypertrophic cardio-
11
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
K
262 Boonyasirinant et al. JACC Vol. 54, No. 3, 2009
Abnormal Aortic Stiffness in HCM July 14, 2009:255–62myopathy with gadolinium cardiovascular magnetic resonance. J Am
Coll Cardiol 2003;41:1561–7.
4. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency
of arrhythmias in hypertrophic cardiomyopathy in relation to delayed
enhancement on cardiovascular magnetic resonance. J Am Coll Car-
diol 2008;51:1369–74.
5. Metafratzi ZM, Efremidis SC, Skopelitou AS, de Roos A. The clinical
significance of aortic compliance and its assessment with magnetic
resonance imaging. J Cardiovasc Magn Reson 2002;4:481–91.
6. London GM, Cohn JN. Prognostic application of arterial stiffness:
task forces. Am J Hypertens 2002;15:754–8.
7. Grotenhuis HB, Ottenkamp J, Westenberg JJ, Bax JJ, Kroft LJ, de
Roos A. Reduced aortic elasticity and dilatation are associated with
aortic regurgitation and left ventricular hypertrophy in nonstenotic
bicuspid aortic valve patients. J Am Coll Cardiol 2007;49:1660–5.
8. Rogers WJ, Hu YL, Coast D, et al. Age-associated changes in regional
aortic pulse wave velocity. J Am Coll Cardiol 2001;38:1123–9.
9. Petersen SE, Wiesmann F, Hudsmith LE, et al. Functional and
structural vascular remodeling in elite rowers assessed by cardiovascular
magnetic resonance. J Am Coll Cardiol 2006;48:790–7.
0. van der Meer RW, Diamant M, Westenberg JJ, et al. Magnetic
resonance assessment of aortic pulse wave velocity, aortic distensibility,
and cardiac function in uncomplicated type 2 diabetes mellitus.
J Cardiovasc Magn Reson 2007;9:645–51.
1. Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients
with hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;48:
2410 –22.
2. Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed
enhancement cardiovascular magnetic resonance assessment of non-
ischaemic cardiomyopathies. Eur Heart J 2005;26:1461–74.
3. Stevanov M, Baruthio J, Gounot D, Grucker D. In vitro validation of
MR measurements of arterial pulse-wave velocity in the presence of
reflected waves. J Magn Reson Imaging 2001;14:120–7.
4. Bland JM, Altman DG. Statistical methods for assessing agreement
between two methods of clinical measurement. Lancet 1986;1:307–10.
5. Mohiaddin RH, Firmin DN, Longmore DB. Age-related changes of
human aortic flow wave velocity measured noninvasively by magnetic
resonance imaging. J Appl Physiol 1993;74:492–7.
6. Auseon AJ, Tran T, Garcia AM, et al. Aortic pathophysiology by
cardiovascular magnetic resonance in patients with clinical suspicion of
coronary artery disease. J Cardiovasc Magn Reson 2007;9:43–8.
7. Rerkpattanapipat P, Hundley WG, Link KM, et al. Relation of aortic
distensibility determined by magnetic resonance imaging in patients
or60 years of age to systolic heart failure and exercise capacity. Am J
Cardiol 2002;90:1221–5.
8. Adams JN, Brooks M, Redpath TW, et al. Aortic distensibility and
stiffness index measured by magnetic resonance imaging in patients
with Marfan’s syndrome. Br Heart J 1995;73:265–9.
9. Franklin SS. Arterial stiffness: is it ready for prime time? Curr Cardiol
Rep 2007;9:462–9.
0. Laurent S, Cockcroft J, Van BL, et al. Expert consensus document on
arterial stiffness: methodological issues and clinical applications. Eur
Heart J 2006;27:2588–605.
1. Zoungas S, Asmar RP. Arterial stiffness and cardiovascular outcome.
Clin Exp Pharmacol Physiol 2007;34:647–51.
2. McVeigh GE, Hamilton PK, Morgan DR. Evaluation of mechanical
arterial properties: clinical, experimental and therapeutic aspects. Clin
Sci (Lond) 2002;102:51–67. c3. O’Rourke MF, Staessen JA, Vlachopoulos C, Duprez D, Plante GE.
Clinical applications of arterial stiffness; definitions and reference
values. Am J Hypertens 2002;15:426–44.
4. Karamanoglu M, O’Rourke MF, Avolio AP, Kelly RP. An analysis of
the relationship between central aortic and peripheral upper limb
pressure waves in man. Eur Heart J 1993;14:160–7.
5. Protogerou AD, Papaioannou TG, Blacher J, Papamichael CM,
Lekakis JP, Safar ME. Central blood pressures: do we need them in
the management of cardiovascular disease? Is it a feasible therapeutic
target? J Hypertens 2007;25:265–72.
6. Karamanoglu M. Errors in estimating propagation distances in pulse
wave velocity. Hypertension 2003;41:e8.
7. Groenink M, de Roos A, Mulder BJ, et al. Biophysical properties of
the normal-sized aorta in patients with Marfan syndrome: evaluation
with MR flow mapping. Radiology 2001;219:535–40.
8. Zelis R, Mason DT. Diminished forearm arteriolar dilator capacity
produced by mineralocorticoid-induced salt retention in man. Impli-
cations concerning congestive heart failure and vascular stiffness.
Circulation 1970;41:589–92.
9. Khan Z, Millard RW, Gabel M, Walsh RA, Hoit BD. Effect of
congestive heart failure on in vivo canine aortic elastic properties. J Am
Coll Cardiol 1999;33:267–72.
0. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna
WJ. Abnormal blood pressure response during exercise in hypertrophic
cardiomyopathy. Circulation 1990;82:1995–2002.
1. Mark AL, Kioschos JM, Abboud FM, Heistad DD, Schmid PG.
Abnormal vascular responses to exercise in patients with aortic
stenosis. J Clin Invest 1973;52:1138–46.
2. Popovic ZB, Kwon DH, Mishra M, et al. Association between
regional ventricular function and myocardial fibrosis in hypertrophic
cardiomyopathy assessed by speckle tracking echocardiography and
delayed hyperenhancement magnetic resonance imaging. J Am Soc
Echocardiogr 2008;21:1299–305.
3. Lartaud-Idjouadiene I, Lompre AM, Kieffer P, Colas T, Atkinson J.
Cardiac consequences of prolonged exposure to an isolated increase in
aortic stiffness. Hypertension 1999;34:63–9.
4. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse
pressure useful in predicting risk for coronary heart disease? The
Framingham heart study Circulation 1999;100:354–60.
5. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for
myocardial infarction and heart failure in the elderly. J Am Coll
Cardiol 2000;36:130–8.
6. Chae CU, Pfeffer MA, Glynn RJ, Mitchell GF, Taylor JO, Hennek-
ens CH. Increased pulse pressure and risk of heart failure in the
elderly. JAMA 1999;281:634–9.
7. Kelly RP, Tunin R, Kass DA. Effect of reduced aortic compliance on
cardiac efficiency and contractile function of in situ canine left
ventricle. Circ Res 1992;71:490–502.
8. Sullivan MJ, Cobb FR. Central hemodynamic response to exercise in
patients with chronic heart failure. Chest 1992;101:340S–6S.
9. Austin BA, Kwon DH, Dumont C, et al. Ventricular-vascular stiff-
ening is more strongly associated with exercise capacity compared to
left ventricular outflow tract gradient in hypertrophic cardiomyopathy
(abstr). J Am Coll Cardiol 2008;51 Suppl 1:A55.
ey Words: aortic stiffness y pulse wave velocity y hypertrophic
ardiomyopathy y myocardial fibrosis y magnetic resonance imaging.
